Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Safety of Transcranial Direct Current Stimulation in the Subacute Phase After Stroke (NEUROSTIM)

25 de septiembre de 2018 actualizado por: Hospital Israelita Albert Einstein

Stroke is the second cause of death worldwide and represented the first cause of death in Brazil between 2006 and 2010. Most patients survive, and there is a need to develop cost-effective rehabilitation strategies to decrease the burden of disability from stroke.

This study addresses this important issue, by evaluating, in the early phase post-stroke, effects of motor conventional physical therapy associated or not with transcranial direct current stimulation (tDCS).

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

The investigators main goal is to confirm the safety of transcranial direct current stimulation (tDCS) associated with conventional physical therapy, compared to conventional physical therapy associated with sham tDCS, for upper limb rehabilitation in an early phase (72 hours until 6 weeks) after stroke. Patients will be randomized to receive one of these two treatments, 3 times per week, for 2 weeks. Adverse effects will be monitored during each session. The working hypothesis is that conventional physical therapy associated with active tDCS in the subacute phase of ischemic stroke will be as safe as conventional therapy alone. The investigators will also preliminarily evaluate the efficacy of active tDCS associated with conventional therapy, compared to conventional therapy alone, in improvement of upper limb motor impairment. The investigators secondary goals are: 1) To compare effects of the above mentioned interventions on disability, spasticity and quality of life, in patients at an early stage after stroke ( subacute phase), immediately after treatment and 3 months later. The investigators hypothesis is that the association of conventional physical therapy and active tDCS will lead to better outcomes than conventional therapy alone. Patients will be assessed before the first session and after the last session of treatment, as well as 3 months after the last session of treatment.

Preliminary data about structural and functional connectivity will be collected in order to plan future studies related to mechanisms of tDCS in the subacute phase after stroke.

Tipo de estudio

Intervencionista

Inscripción (Actual)

30

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Sao Paulo, Brasil, 05652-901
        • Danielle Boasquevisque

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Ischemic stroke confirmed by computed tomography or magnetic resonance imaging, with onset between 72 hours and 6 weeks before enrollment.
  • Unilateral paresis of upper limb
  • National Institute of Health Stroke Scale ( NIHSS) score of at least 1 point in items 5a or 5b .
  • Ability to provide written informed consent (patient ou legal representative).

Exclusion Criteria:

  • Lesions affecting the corticomotor pathway in the hemisphere contralateral to the stroke.
  • Neurologic diseases except migraine.
  • Modified Rankin Scale > 2 prior to stroke.
  • Advanced systemic disease such as cancer or advanced chronic renal disease.
  • Clinical instability such as uncontrolled cardiac arrhythmia or heart failure.
  • Contraindication for physical therapy.
  • Pregnancy.
  • Absolute or relative contraindications to tDCS: metallic prosthesis in the head or neck; lesions on the scalp, history of neurosurgery, pacemaker.
  • Comprehension aphasia
  • Dementia
  • Cerebellar stroke or ataxia caused by involvement of cerebellar pathways in the brainstem

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Active tDCS+ Physical Therapy
Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Physical therapy will be administered for 60 minutes
Comparador falso: Sham tDCS+Physical Therapy

Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.

Number of treatment sessions: 6 (3 times a week, for 2 weeks)

In sham tDCS, no current will be delivered through the tDCS device.
Physical therapy will be administered for 60 minutes

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety of the intervention as assessed by frequency of adverse events
Periodo de tiempo: 2 weeks
frequency of adverse events in the active and sham arms
2 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Improvement post treatment as measured by the Modified Rankin Scale
Periodo de tiempo: 2 weeks and 14 weeks
Improvement post treatment
2 weeks and 14 weeks
Improvement post treatment as measured by the NIH Stroke Scale
Periodo de tiempo: 2 weeks and 14 weeks
Improvement post treatment
2 weeks and 14 weeks
Improvement post treatment as measured by the Stroke Impact Scale
Periodo de tiempo: 2 weeks and 14 weeks
Improvement post treatment
2 weeks and 14 weeks
Upper limb subscale of Fugl Meyer Assessment of Sensorimotor recovery after stroke
Periodo de tiempo: 2 weeks and 14 weeks
Improvement post treatment
2 weeks and 14 weeks
Improvement post treatment as measured by the Modified Ashworth Scale
Periodo de tiempo: 2 weeks and 14 weeks
Improvement post treatment
2 weeks and 14 weeks
Improvement post treatment as measured by the Motor Activity Log
Periodo de tiempo: 2 weeks and 14 weeks
Improvement post treatment
2 weeks and 14 weeks
Montreal Cognitive Assessment Test
Periodo de tiempo: 2 weeks and 14 weeks
No cognitive deterioration post treatment
2 weeks and 14 weeks
Structural Connectivity as measured by diffusion tensor imaging analysis
Periodo de tiempo: 2 weeks
Improvement post treatment
2 weeks
Functional Connectivity as measured by resting-state functional magnetic imaging analysis
Periodo de tiempo: 2 weeks
Improvement post treatment
2 weeks
Improvement post treatment as measured by the Barthel index
Periodo de tiempo: 2 week and 14 weeks
Improvement post treatment
2 week and 14 weeks
Safety of the intervention as assessed by frequency of adverse events
Periodo de tiempo: 14 weeks
frequency of adverse events in the active and sham arms
14 weeks
Improvement post treatment as measured by Pittsburgh Sleep Quality Index
Periodo de tiempo: 2 week and 14 weeks
Improvement post treatment
2 week and 14 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Adriana B Conforto, MD Phd, Hospital Israelita Albert Einstein

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de mayo de 2015

Finalización primaria (Actual)

31 de marzo de 2018

Finalización del estudio (Actual)

31 de marzo de 2018

Fechas de registro del estudio

Enviado por primera vez

24 de abril de 2015

Primero enviado que cumplió con los criterios de control de calidad

22 de mayo de 2015

Publicado por primera vez (Estimar)

27 de mayo de 2015

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de septiembre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

25 de septiembre de 2018

Última verificación

1 de septiembre de 2018

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

No

Descripción del plan IPD

Deidentified imaging data will be shared with collaborators

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Sham tDCS

Suscribir